Naratriptan

被引：22

作者：

Gunasekara N.S. ^{[1
,2
]}

Wiseman L.R. ^{[1
]}

机构：

[1] Adis International Limited, Auckland

[2] Adis International Ltd, Mairnngi Bay, Auckland 10

来源：

CNS Drugs | 1997年 / 8卷 / 5期

关键词：

Migraine; Adis International Limited; Sumatriptan; Myocardial Blood Flow; Triptan;

D O I：

10.2165/00023210-199708050-00006

中图分类号：

学科分类号：

摘要：

Naratriptan is a new serotonin 5-HT(1B/1D) receptor agonist that is indicated for the acute treatment of migraine. In vitro and in vive studies indicate that naratriptan mediates vasoconstriction in the cerebral vasculature and inhibits responses mediated by the trigeminal nerve. Studies in healthy volunteers demonstrate that naratriptan has good oral bioavailability. Naratriptan is effective in alleviating migraine headache and associated symptoms such as photophobia, phonophobia and nausea. It is also effective in preventing the recurrence of headache symptoms. In general the efficacy of naratriptan is similar to that of sumatriptan in treating migraine; however, naratriptan is associated with a lower incidence of headache recurrence than sumatriptan. Studies have shown that the tolerability of naratriptan is good, with the overall incidence of adverse events during treatment with naratriptan at doses up to 2.5mg similar to that observed with placebo. Naratriptan had no clinically significant effect on blood pressure or heart rate.

引用

页码：402 / 408

页数：6

共 24 条

[1]

Lance J.W., Current concepts of migraine pathogenesis, Neurology, 43, 3 SUPPL., (1993)

[2]

Connor H.E., Feniuk W., Beattie D.T., Et al., Naratriptan: Biological profile in animal models relevant to migraine, Cephalalgia, 17, pp. 145-152, (1997)

[3]

Swan L., Birnie D.H., Hood S., Et al., The effects of subcutaneous naratriptan 1.5 mg on the systemic, pulmonary, and coronary circulation in patients with suspected coronary artery disease, Cephalalgia, 17, (1997)

[4]

Camici P., Melin J., Gnecchi-Ruscone T., Et al., A study of the effect of subcutaneous naratriptan 1.5 mg on mvocardial perfusion in migraineurs using positron emission tomography, Cephalalgia, 17, (1997)

[5]

Camici P.G., Melin J., Gnecchi-Ruscone T., Et al., A study of the effects of subcutaneous naruuiptan 1.5mg on myocardial perfusion in migraineurs using positron emission tomography, 8th Congress of the International Headache Society, (1997)

[6]

Yogendran L., Boswell D., Winter P., Et al., Subcutaneous naratriptan (1mg, 5mg and 10mg) has no effect on peripheral blood How as measured by forearm blood How, Cephalalgia, 17, (1997)

[7]

Kempsford R.D., Hoke J.F., Huffman C.S., The safety, tolerahility and pharmacokinetics of oral naratriplan in healthy subjects, Cephalalgia, 17, pp. 416-417, (1997)

[8]

Kempsford R.D., Lacey L.F., Keene O.N., The safely, tolerability and pharmacokinetics of subcutaneous GR85548, a novel 5-HT<sub>1</sub>-receptor agonist for the treatment of migraine, Br J Clin Pharmacol, 36, (1993)

[9]

Mathew N.T., Peykamian M., Laurenza A., Et al., Efficacy and tolerability of naratriptan tablets in the treatment of migraine: Results of a double-blind, placebo-controlled. crossover trial, Cephalalgia, 17, (1997)

[10]

Knight Y.E., Goadsby P.J., Naratriptan inhibits central trigeminal neurons after systemic administration by a 5-HT<sub>(1B/1D)</sub> receptor in cat, Cephulalgia, 17, (1997)

← 1 2 3 →